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and/orIntroduction
The most recent American College of Cardiology Founda-
tion/American Heart Association/Heart Rhythm Society
(ACCF/AHA/HRS) guidelines related to pacemaker implan-
tation were published as part of a larger document related to
device-based therapy (1). While this document provides some
comments on pacemaker mode selection and algorithms to guide
selection, it does not provide specific recommendations regard-
ing choices for single- or dual-chamber devices. Over the past 15
years multiple randomized trials have compared a number of
cardiovascular outcomes among patients randomized to atrial or
dual-chamber pacing vs. those randomized to ventricular pacing.
The purpose of this 2012 consensus statement is to provide a
state-of-the-art review of the field and to report the recommen-
dations of a consensus writing group, convened by HRS and
ACCF, on pacemaker device and mode selection. This docu-
ment focuses on pacemaker device and mode selection in the
adult patient; therefore, many of the recommendations may not
be applicable to unique situations encountered in the pediatric
population. These recommendations summarize the opinion of
the consensus writing group, based on an extensive literature
review as well as their own experience.
This document should be used as a supplement to the
published 2008 guidelines document, functioning as a guide to
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mendations for device selection in the current docu-
ment apply to situations where the clinical decision for
pacing has already been made. In addition, specific recom-
mendations for cardiac resynchronization therapy are not
addressed in this document as the indications for cardiac
resynchronization therapy have been published previously
and guideline updates related to these indications are also
in progress (2,3).
This document is directed to all health care professionals
who are involved in the selection of devices and pacing mode
as well as the subsequent management of patients with
pacemakers.
All recommendations provided were agreed upon by at
least 81% of the writing committee by anonymous vote.
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectionass and level of evidence designations to provide consis-
ncy with familiar guideline documents.
lassification of Recommendations
Class I: Conditions for which there is evidence and/or general
agreement that a given pacing mode is beneficial, useful and
effective.
Class II: Conditions for which there is conflicting evidence
and/or divergence of opinion about the usefulness/efficacy of
a specific pacing mode.
X Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
X Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
Class III: Conditions for which there is conflicting evidence
and/or general agreement that a pacing mode is not useful/
effective and in some cases may be harmful.
evel of Evidence
Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard of care.
The writing group was divided into three subgroups to
view aspects of pacing mode selection for patients with 1)
nus node dysfunction (SND), 2) atrioventricular (AV)
nduction block, and 3) other less common indications for
cing. All members of the writing group, as well as peer
viewers of the document, provided disclosure statements
r all relationships that might be perceived as real or
tential conflicts of interest. These tables are shown at the
d of this document.
. Pacemaker Device and Mode
election for SND
xpert Consensus Recommendations (see Table 1 for a
mmary of consensus recommendations)
ASS I
Dual-chamber pacing (DDD) or single-chamber atrial pacing
(AAI) is recommended over single-chamber ventricular pacing
(VVI) in patients with SND and intact AV conduction (Level of
Evidence: A) (5–9).
Dual-chamber pacing is recommended over single-chamber
atrial pacing in patients with SND (Level of Evidence: B) (10).
ASS IIa
Rate adaptive pacing can be useful in patients with significant
symptomatic chronotropic incompetence, and its need should
be reevaluated during follow-up (Level of Evidence: C) (11,12).
In patients with SND and intact AV conduction, programming
dual-chamber pacemakers to minimize ventricular pacing can wbe useful for prevention of atrial fibrillation (AF) (Level of
Evidence: B) (13).
ASS IIb
AAI pacing may be considered in selected patients with normal
AV and ventricular conduction (Level of Evidence: B) (14–16).
Single-chamber VVI pacing may be considered in instances
where frequent pacing is not expected or the patient has
significant comorbidities that are likely to influence survival
and clinical outcomes (Level of Evidence: C) (5–8).
ASS III
Dual-chamber pacing or single-chamber atrial pacing should not
be used in patients in permanent or longstanding persistent AF
where efforts to restore or maintain sinus rhythm are not planned
(Level of Evidence: C) (1,5,10,17,18).
SND is the most common cause of bradyarrhythmias
quiring pacing therapy in North America and Western
urope. Arrhythmias associated with SND include sinus
adycardia, sinoatrial block, sinus arrest, chronotropic in-
mpetence, and tachycardia–bradycardia syndrome charac-
rized by paroxysms of supraventricular tachyarrhythmias
F, atrial flutter, atrial tachycardia) alternating with brady-
rdia or asystole (17). Twenty percent of patients with SND
ill have some degree of AV block (8).
Two important developments in the natural history of SND
ould be emphasized: AV block and AF (17,19). The risk of
veloping AV block following pacemaker implantation
ithin 5 years of follow-up is 3–35% (15,16,19,20). This risk
ries with patient factors including age and comorbidities
d likely increases further over time and with the addition of
edications that have negative dromotropic effects. In pa-
ents with SND, the incidence of clinical AF at the time of
itial diagnosis has been reported to range from approxi-
ately 40–70% (8,10,21). Among patients who do not have
F at initial diagnosis, the incidence of new AF in follow-up
nges from 3.9–22.3% (8,10,21). During long-term follow-
, 68% of patients receiving a dual pacemaker for SND
ve had AF documented by device diagnostics (21). The
cidence of AF is significantly influenced by mode of
cing, percentage of ventricular pacing, and duration of
llow-up (17,19,21).
In the absence of a reversible cause, the appropriate
eatment for symptomatic SND is implantation of a perma-
nt pacemaker. Available pacing modes include dual-
amber (DDD or DDI), ventricular single-chamber (VVI),
d atrial single-chamber (AAI). Rate adaptive pacing may
programmed as required for symptomatic chronotropic
competence. The optimal pacing mode for patients with
ND has generated much debate until the completion and
blication of several landmark clinical trials reporting the
periority of atrial or dual-chamber pacing over ventricular
cing with regard to their effect on some clinical outcomes.
Four major randomized clinical trials, specifically the
anish study, the Pacemaker Selection in the Elderly (PASE)
udy, the Canadian Trial of Physiologic Pacing (CTOPP),
d the Mode Selection Trial (MOST), have compared atrial
dual-chamber pacing with ventricular pacing in patientsith SND (5–8,14). These randomized controlled trials
Table 1. Consensus Recommendations for Device and Mode Selection Apply to Situations Where the Clinical Decision for Pacing has Already Been Made
Class I Class IIa Class IIb Class III
Sinus Node
Dysfunction
1. Dual-chamber pacing (DDD) or single-chamber atrial pacing (AAI) is
recommended over single-chamber ventricular pacing (VVI) in patients
with SND and intact AV conduction (Level of Evidence: A)
1. Rate adaptive pacing can be useful in patients
with significant symptomatic chronotropic
incompetence and its need should be
reevaluated during follow-up (Level of
Evidence: C)
1. AAI pacing may be considered in
selected patients with normal AV
and ventricular conduction (Level
of Evidence B)
1. Dual-chamber pacing or single-chamber
atrial pacing should not be used in patients
in permanent or longstanding persistent AF
in whom efforts to restore or maintain
sinus rhythm are not planned (Level of
Evidence: C)
2. Dual-chamber pacing is recommended over single-chamber atrial
pacing in patients with SND (Level of Evidence: B)
2. In patients with SND and intact AV conduction,
programming dual-chamber pacemakers to
minimize ventricular pacing can be useful for
prevention of atrial fibrillation (AF) (Level of
Evidence: B)
2. Single-chamber VVI pacing may
be considered in instances
where frequent pacing is not
expected or the patient has
significant comorbidities that
are likely to influence survival
and clinical outcomes (Level of
Evidence: C)
AV Node Disease 1. Dual-chamber pacing is recommended in patients with AV block
(Level of Evidence: C)
1. Single-lead, dual-chamber VDD pacing can be
useful in patients with normal sinus node
function and AV block (e.g., the younger
patient with congenital AV block) (Level of
Evidence: C)
1. Dual-chamber pacing should not be used in
patients with AV block in permanent or
longstanding persistent AF in whom efforts to
restore or maintain sinus rhythm are not
planned (Level of Evidence: C)
2. Single-chamber ventricular pacing is recommended as an
acceptable alternative to dual-chamber pacing in patients with AV
block who have specific clinical situations that limit the benefits of
dual-chamber pacing. These include, but are not limited to,
sedentary patients, those with significant medical comorbidities
likely to impact clinical outcomes, and those in whom technical
issues, such as vascular access limitations, preclude or increase the
risk of placing an atrial lead (Level of Evidence: B)
2. VVI pacing can be useful in patients following
AV junction ablation, or in whom AV junction
ablation is planned, for rate control of AF due
to the high rate of progression to permanent
AF (Level of evidence B)
3. Dual-chamber pacing is recommended over single-chamber
ventricular pacing in adult patients with AV block who have
documented pacemaker syndrome (Level of Evidence: B)
Hypersensitive
Carotid Sinus
Syndrome
1. Dual-chamber or single-chamber ventricular
pacing can be useful for patients with
hypersensitive carotid sinus syndrome (Level of
Evidence: C)
1. Single-chamber AAI pacing is not
recommended for patients with hypersensitive
carotid sinus syndrome (Level of Evidence: C)
Neurocardiogenic
Syncope
1. Dual-chamber pacing can be useful for
neurocardiogenic syncope (Level of Evidence: C)
1. Single-chamber AAI pacing is not
recommended for neurocardiogenic syncope
(Level of Evidence: C)
Long QT 1. Dual-chamber or atrial pacing compared to ventricular pacing is
recommended for symptomatic or high-risk patients with congenital
long QT syndrome (Level of Evidence: C)
Hypertrophic
Cardiomyopathy
1. Dual-chamber pacing can be useful for
patients with medically refractory, symptomatic
hypertrophic cardiomyopathy with significant
resting or provoked left ventricular outflow
obstruction (Level of Evidence: C)
1. Single-chamber (VVI or AAI) pacing is not
recommended for patients with medically
refractory, symptomatic hypertrophic
cardiomyopathy (Level of Evidence: C)
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectioncluded mostly elderly patients (mean age 72–76 years),
any of whom had several comorbidities. PASE and CTOPP
cluded a general pacemaker population with 42% having
ND. The vast majority of patients in these studies, random-
ed to atrial-based pacing, received dual-chamber devices.
hese trials are summarized in Table 2 and Figure 1. When
terpreting the results of these trials, some limitations should
considered. The crossover from one arm of the study to the
her (typically VVI to DDD) was variable, ranging from less
an 5% over 3 years in CTOPP, which required reoperation
d addition of an atrial lead, to 37.6% over 3 years in
OST, which was accomplished simply by reprogramming
e pulse generator to the DDD mode (5–8,14). In addition,
e percentage of atrial and ventricular pacing was not
ported in the Danish study, CTOPP, or PASE (5,6,14). A
mmary of the effects of pacing mode on important clinical
dpoints in these clinical trials is presented below.
.1. AF
trial or dual-chamber pacing compared to ventricular pacing
gnificantly reduced AF in the Danish, CTOPP, and MOST
udy populations with relative risk reductions of 46%, 18%,
d 21% respectively (Table 2) (6–8,14). In CTOPP, a
neral pacemaker population, the number needed to treat to
event any AF over 10 years was 9 patients, and in MOST
e number needed to treat to prevent permanent AF over 3
ars was 9 patients (17). A meta-analysis of these clinical
ials (that also pooled data from the United Kingdom Pacing
d Cardiovascular Events, UK-PACE, a trial that included
ly patients with AV block [22]) showed a highly significant
% relative risk reduction (hazard ratio [HR] 0.80, 95%
nfidence interval [CI] 0.72–0.89, p  0.00003) in AF with
rial or dual-chamber pacing compared to ventricular pacing
igure 2) (9). Device diagnostics in atrial and dual-chamber
cemakers permit detection of episodes of AF that may not
ve been previously identified, thus facilitating a decision
out the appropriateness of antithrombotic therapy based on
sk for stroke (23,24). Although not the primary endpoint of
e above randomized trials, prevention of AF is an important
inical outcome for clinicians to consider when making
cisions about permanent pacing in patients with SND. This
nsideration is based upon the association of AF with an
paired quality of life and increased morbidity related to
roke and other clinical outcomes, as well as the cost of
erapies to control AF and prevent or treat these problems
ee Recommendations Table 1) (25).
.2. Stroke/Thromboembolism
lthough the Danish study showed a 53% relative reduction
the risk of systemic thromboembolism with AAI compared
VVI pacing, none of the other studies could replicate this
nding (Table 2). However, the meta-analysis of the pooled
ta reported a significant reduction in the risk of stroke with
rial-based pacing (HR 0.81, 95% CI 0.67–0.99, p  0.035;
igure 3) (9). Such an effect is consistent with the reductionAF observed with atrial or dual-chamber pacing. in.3. Heart Failure
ompared with ventricular pacing (VVI), atrial pacing (AAI)
proved the heart failure status of patients enrolled in the
anish study (Table 2) (14). In MOST, heart failure occurred
10.3% of the dual-chamber (DDDR) group and 12.3% of
e ventricular pacing (VVIR) group (HR 0.82, 95% CI
63–1.06, p  0.13) (8). However, after an adjusted analysis
address some imbalances in clinical characteristics be-
een the two groups, hospitalization for heart failure was
gnificantly lower with dual-chamber pacing than ventricular
cing (HR 0.73, 95% CI 0.56–0.95, p  0.02). In addition,
ring follow-up in MOST, patients with dual-chamber
cing had a significantly lower heart failure score than
tients with ventricular pacing (p 0.001) (8). However,
ASE, CTOPP, and the afore-mentioned meta-analysis failed
show a significant reduction in heart failure by atrial or
al-chamber pacing (6–9).
.4. Mortality
xcept for the Danish study (14), none of these randomized
inical trials showed a significant difference in cardiovascu-
r mortality between atrial or dual-chamber pacing and
ntricular pacing (Table 2) (6,8,10). Likewise, the meta-
alysis of the pooled data demonstrated no significant
duction in mortality with atrial-based pacing compared to
ntricular pacing (Figure 1) (9).
.5. Quality of Life and Functional Status
ASE, CTOPP, and MOST examined the effect of pacing
ode on the quality of life and functional status (5,26,27).
TOPP showed no significant effect of pacing mode on the
ality of life. However, an improvement in exercise
pacity, as assessed by the distance walked in 6 minutes,
as observed in the atrial or dual-chamber pacing sub-
oup with a high degree of pacing (26,28,29). In patients
ith SND enrolled in PASE, dual-chamber pacing was
sociated with improved quality of life and cardiovascular
nctional status compared to ventricular pacing (5). In
OST, dual-chamber pacing resulted in a significant
provement in some subscales of quality of life as
sessed by the SF-36 instrument, specifically role physi-
l, role emotional, and vitality (27).
.6. Pacemaker Syndrome
acemaker syndrome is the occurrence of overt symptoms,
ch as fatigue, chest discomfort, dyspnea, cough, confusion,
esyncope, or syncope due to adverse hemodynamics that
sult from loss of AV synchrony and occurrence of ventricu-
atrial conduction or atrial contraction against closed AV valves
patients with an implanted pacemaker (30). Although pace-
aker syndrome may occur with any mode of pacing, it is most
mmon with ventricular pacing in the VVI mode in patients
ho are in sinus rhythm. One randomized clinical trial compared
different symptoms and hemodynamic parameters among 40
tients in sinus rhythm who were randomly programmed to the
VI mode or the DDD mode. Patients were blinded to the mode
pacing. Twelve of sixteen symptoms were significantly worse
the VVI mode, with a mean symptom score of 29.0 26.1 in
Table 2. Major Randomized Controlled Trials*
Characteristics Danish Study (14) PASE (5) CTOPP (6,7) MOST (8) DANPACE (10) UKPACE (22)
Patient population SSS SSS plus AVB SSS plus AVB SSS SSS AVB
Patients with SSS/AVB 220/0 175/232 1,028/1,540 2,010/0 1,415/0 0/2,021
Mean or median
follow-up (yr)
5.5 1.5 3.5
6.4 (extended CTOPP)
2.8 5.4 3.0
Pacing modes AAI vs. VVI DDDR vs. VVIR DDD/AAI vs. VVI(R) DDDR vs. VVIR AAIR vs. DDDR DDD(R) vs. VVI(R)
Primary endpoint Composite of mortality,
thromboembolism and AF
Health-related quality of life as
measured by the SF-36
Stroke or CV mortality All-cause mortality or nonfatal stroke All-cause mortality All-cause mortality
Secondary endpoints CV mortality, HF, and AVB All-cause mortality, nonfatal stroke,
AF, and pacemaker syndrome
All-cause mortality, AF,
HF hospitalization
Composite of all-cause mortality, first
stroke, first HF; all-cause mortality; CV
mortality; AF; pacemaker syndrome;
health-related quality of life;
Minnesota Living with HF score
Incidence of paroxysmal and chronic
AF, stroke, HF, need for pacemaker
reoperation
AF; HF; composite
of stroke, transient
ischemic attack,
or other
thromboembolism
Atrial fibrillation 24% AAI vs. 35% VVI RRR
46%, p  0.012
19% VVIR vs. 17% DDDR, p  0.80 Annual rate 6.6% VVI vs.
5.3% DDD/AAI, RRR 18%,
p  0.05
Extended CTOPP: Annual
rate 5.7% VVI vs. 4.5%
DDD/AAI, RRR 20.1%,
p  0.009
27.1% VVIR vs. 21.4% DDDR, RRR
21%, p  0.008
28.4% AAIR vs. 23.0% DDDR, RRR
27%, p  0.024
Annual rate 3.0%
VVI/VVIR vs. 2.8%
DDD/DDDR,
p  0.74
Stroke/thromboembolism 12% AAI vs. 23% VVI RRR
53%, p  0.023
Annual rate 1.1% VVI vs.
1.0% DDD/AAI, p  NS
(Extended CTOPP:
Remained NS)
4.9% VVIR vs. 4.0% DDDR, RRR 18%,
p  0.36
5.5% AAIR vs. 4.8% DDDR, RRR
13%, p  0.59
Annual rate 2.1%
VVI/VVIR vs. 1.7%
DDD/DDDR,
p  0.20
Heart failure or
hospitalization for
heart failure
Annual rate 3.5% VVI vs.
3.1% DDD/AAI, RRR 7.9%,
p  0.52
12.3% VVIR vs. 10.3% DDDR, RRR
18%, p  0.13
Annual rate 3.2%
VVI/VVIR vs. 3.3%
DDD/DDDR,
p  0.80
Mortality, all-cause 35% AAI vs. 50% VVI RRR
34%, p  0.045
17% VVI vs. 16% DDDR, p  0.95 Annual rate 6.6% VVI vs.
6.3% DDD/AAI, RRR .9%,
p  0.92 (Extended
CTOPP: Remained NS)
20.5% VVIR vs. 19.7% DDDR, RRR
3%, p  0.78
29.6% AAIR vs. 27.3% DDDR, RRR
6%, p  0.53
Annual rate 7.2%
VVI/VVIR vs. 7.4%
DDD/DDDR,
p  0.56
Cardiovascular mortality 17% AAI vs. 34% VVI RRR
53%, p  0.0065
9.2% VVIR vs. 8.5% DDDR, RRR 7%,
p  0.61
Annual rate 3.9%
VVI/VVIR vs. 4.5%
DDD/DDDR,
p  0.07
*Outcomes for AF, stroke/thromboembolism, heart failure, mortality, and CV mortality are listed as overall absolute event rates or mean annual event rates (when specified).
AF  atrial fibrillation; AVB  AV block; CV  cardiovascular; HF  heart failure; NS  not significant; RRR  relative risk reduction; SSS  sick sinus syndrome.
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectione VVI group compared with 7.3  12.4 in the DDD or DDI
oup (p 0.001). Importantly, pacemaker syndrome was clin-
ally recognized in 83% of patients paced in the VVI mode;
% of all patients experienced development or exacerbation of
oderate to severe symptoms in the VVI mode compared with
e dual-chamber pacing mode (31). Some of these symptoms
ay have been dependent on the underlying baseline or sensor-
gure 1. Effect of pacing mode on all-cause mortality expressed
1.0 is shown to the left of the center line and favors atrial-based
eprinted with permission from Healey et al. (9).
gure 2. Effect of pacing mode on atrial fibrillation expressed as
e and favors atrial-based pacing. CIs that cross 1.0 signify a sta
al. (9).iven ventricular rate among patients programmed in the VVI
ode (32). In some patients, pacemaker syndrome can be
evented by programming backup VVI pacing at a lower
ntricular rate.
Many small early crossover studies of dual-chamber vs.
VI pacing, which evaluated quality of life and functional
pacity, consistently showed a marked benefit and prefer-
hazard ratio (HR) and 95% confidence interval (CI). An HR
. CIs that cross 1.0 signify a statistically nonsignificant effect.
and 95% CI. An HR  1.0 is shown to the left of the center
ly nonsignificant effect. Reprinted with permission from Healeyas the
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HRS/ACCF Pacemaker Mode Selection August 14, 2012:682–703ce for DDD pacing compared to VVI pacing. In the PASE
ial, 26% of the patients randomized to VVIR pacing needed
crossover to dual-chamber pacing due to severe pacemaker
ndrome (33). A significant improvement in the quality of
fe was observed in these patients with reestablishment of
V synchrony. In MOST, 38% of patients in the ventricular
cing group had their pacemakers reprogrammed to the
al-chamber pacing mode for symptoms believed to be due
pacemaker syndrome (8). Of the 996 patients randomized
VVIR pacing, 182 (18.3%) developed severe pacemaker
ndrome during follow-up that improved with reprogram-
ing the device to DDDR pacing (33). A systematic review
the literature conducted by the Cochrane Collaboration
ported a significant reduction in the symptoms of pacemaker
ndrome associated with the use of dual-chamber pacing,
mpared to ventricular pacing, for both parallel and crossover
sign studies (34). A limitation of this analysis is the inclusion
patients with both SND and AV block indications for pacing.
is important to emphasize that no baseline parameter or data
tained at pacemaker implantation can be used to reliably
edict the occurrence of clinically significant pacemaker syn-
ome (35,36). Although a blood pressure drop of 20 mm Hg
sociated with symptoms has been used as a definition of
cemaker syndrome, a drop in systolic blood pressure during
ntricular pacing at implantation did not predict development
pacemaker syndrome during follow-up in MOST (33).
.7. Deleterious Effects of
ight Ventricular Pacing
everal studies have reported deleterious effects of right
ntricular pacing, including an increased risk of developing
art failure and an increased burden of AF (18,37–40).
gure 3. Effect of pacing mode on stroke expressed as the HR a
vors atrial-based pacing. CIs that cross 1.0 signify a statisticallyight ventricular apical pacing may cause ventricular dys- panction by creating ventricular dyssynchrony due to an
normal activation sequence (39–42). In 50 patients with
ND randomized to AAIR or DDDR pacing, dyssynchrony
as more pronounced in the DDDR group than in the AAIR
oup at 12 months (p 0.05), reflecting a significant
crease in dyssynchrony in the DDDR group without change
the AAIR group. Left ventricular ejection fraction de-
eased significantly in the DDDR group from baseline to 12
onths (63.1  8% vs. 59.3  8%, p 0.05), while left
ntricular ejection fraction remained unchanged in the
AIR group (61.5  11% vs. 62.3  7%, p  NS), thus
pporting the concept that some degree of ventricular pacing
ay promote structural remodeling in the ventricle (43).
In a clinical trial of 225 patients randomized to atrial
ngle-chamber pacing vs. ventricular single-chamber pacing,
ntricular pacing was associated with a higher risk of heart
ilure (44). In a post-hoc analysis from MOST, a high
mulative percentage of ventricular pacing in 1,339 patients
ith a QRS 120 ms was found to be associated with an
creased risk of heart failure hospitalization and AF (37). As
dicated by the results of the Danish Multicenter Random-
ed Trial on Single Lead Atrial Pacing versus Dual-Chamber
acing in Sick Sinus Syndrome (DANPACE) trial, most
tients with SND have normal left ventricular function and
lerate some degree of right ventricular pacing without devel-
ing heart failure during long-term follow-up (10). Although
t a study of the pacemaker population, the Dual-Chamber and
VI Implantable Defibrillator (DAVID) trial demonstrated that
ght ventricular pacing increased the combined endpoint of
ath or hospitalization for heart failure in patients with standard
dications for implantable cardioverter defibrillator (ICD) ther-
y and left ventricular dysfunction but no indication for cardiac
CI. An HR  1.0 is shown to the left of the center line and
nificant effect. Reprinted with permission from Healey et al. (9).nd 95%cing (38). From the above studies, the percentage of right
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectionntricular pacing that has been implicated as potentially result-
g in a higher risk of heart failure or AF is 40–50%
7,45–47).
Thus, there is strong evidence that a high proportion of
ght ventricular pacing, particularly in patients with some
gree of left ventricular systolic dysfunction, is detrimental,
d every attempt should be made to minimize it. The
trimental effects of right ventricular pacing may be minimal
patients without significant structural heart disease but are
kely amplified in patients with clinical heart failure, a high
rcentage of right ventricular apical pacing, and evidence of
ft ventricular systolic dysfunction. Minimizing right ven-
icular pacing may be achieved effectively by programming
nger AV delays (e.g., 220–250 ms) or implanting pacemak-
s that have specific algorithms for minimizing ventricular
cing (17,48). Such algorithms have been shown to substan-
ally reduce the percentage of ventricular pacing in both
tients with SND and AV block indications for pacing (49).
lgorithms that reduce the cumulative percentage of ventric-
ar pacing also have been reported to lower the burden of AF
d the development of persistent AF during follow-up
3,48). In a retrospective study of 102 patients older than 75
ars with SND, dual-chamber pacemakers with an algorithm to
inimize ventricular pacing were associated with a fewer
mber of heart failure episodes and a lower risk of mortality
an conventional dual-chamber devices (50). The optimal
ogramming algorithm for minimizing ventricular pacing and
timizing clinical outcomes is unknown. Use of these algo-
thms may be inappropriate in patients with a long baseline PR
terval or in whom atrial pacing results in a long PR interval
250 ms) (51). Programming to minimize unnecessary right
ntricular pacing may include turning off rate response in
tients with single-chamber ventricular devices or turning off
e rate responsive AV delay in patients with dual-chamber
vices if these features are not deemed beneficial for a specific
tient.
.8. Is There a Role for Single-Chamber
trial Pacing in SND?
he recently published DANPACE trial supports the prefer-
tial choice of a dual-chamber pacing system to an AAI
cing system for patients with SND and preserved AV
nduction (see Recommendations Table 1) (10). Reasons for
eferring DDD pacing to AAI pacing are the relatively high
sk of AV conduction disease at baseline (up to 20%), the
ogressive risk of developing AV block during follow-up,
d the risk of a significant complication associated with an
erative revision from single-chamber atrial to dual-
amber pacing necessitated by the development of AV block
this population (8,10). In DANPACE, 1,415 patients with
ND were randomized to DDDR pacing or AAIR pacing
0). The criteria for enrollment into DANPACE included a
R interval220 ms if aged 18–70 years or260 ms if aged
70 years, and a QRS duration 120 ms. Exclusion criteria
cluded AV block or bundle branch block. After a mean
llow-up of 5.4 years, no difference was observed with
spect to the primary endpoint—death from any cause—
tween the two treatment arms. AF occurred more com-
only with AAIR pacing than with DDDR pacing (HR 1.27, fi0.02), and the risk of pacemaker reoperation in the AAIR
oup was twice as high when compared with the DDDR
oup. A total of 9.3% of patients (1.7% per year) randomized
AAIR pacing needed an operative revision to a dual-chamber
cing system during the study period despite careful patient
lection. The risk of developing AV block over 34.2 months of
llow-up after implantation of an AAI pacemaker in candidates
nsidered “suitable” for this pacing mode was 8.4%, and this
sk is predicted to increase over a longer duration of follow-up
5,16,19,20). No differences between the two treatment arms
ere observed with respect to stroke or the development of heart
ilure. Considering the risk of AV block with single-lead atrial
cing, together with the documentation that atrial pacing has no
neficial effect on long-term clinical outcomes compared with
al-chamber pacing, plus the incremental complications related
an operative revision to a dual-chamber pacing system,
al-chamber pacing is preferable to atrial pacing in SND.
Previous studies have indicated that frequent ventricular
cing even in an AV synchronous pacing mode increases AF
3). It was therefore an unexpected finding in the DANPACE
ial that AF was significantly less common with DDDR
cing than with AAIR pacing. The use of moderately
olonged and individualized AV intervals in the DDDR
oup in the DANPACE trial may help explain this finding.
rogramming of a moderately prolonged AV interval results
minimal ventricular pacing when the patients have normal
trinsic AV conduction and prevents very prolonged AV
nduction, which also has been associated with AF (51,52).
urthermore, very short AV intervals truncating the atrial
ptying may also be associated with atrial dilatation and
ould be avoided. In addition, a recent meta-analysis of four
inical trials suggests that a high proportion of atrial pacing
ay increase the risk for AF (53). Although the DANPACE
ial suggests that the use of AAIR pacing or pacing modes
imicking AAI would not significantly reduce AF compared
DDDR pacing with the pacemaker programmed with a
oderately prolonged and individualized AV interval, the need
minimize atrial pacing by eliminating rate adaptive program-
ing unless deemed clinically essential must be considered. It is
so important to emphasize that some algorithms that result in
cessive prolongation of the AV interval may be detrimental
der certain clinical circumstances. and thus the use of these
gorithms must be individualized (13,54). These algorithms
ay result in exaggerated AV delays resulting in pacemaker
ndrome as a consequence of atrial contraction early in
astole (17). Timing cycles in the Managed Ventricular
acing (MVP) mode are ventricular based and under some
rcumstances (eg. ventricular premature beat), noncompeti-
ve atrial pacing will extend the V-A interval resulting in an
tension of the next atrial pacing interval. The relative
adycardia or the occurrence of short–long–short ventricular
quences have been reported to cause ventricular proarrhyth-
ia (55–57).
Early clinical trials reported a relatively low rate of
ogression to high-grade AV block in patients selected for
AI pacing (15,16). Since DANPACE included predomi-
ntly elderly patients, an AAI pacing system might be
nsidered in the younger patient (i.e., 70 years at time ofrst implant) with SND and no evidence of AV or ventricular
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HRS/ACCF Pacemaker Mode Selection August 14, 2012:682–703nduction abnormality who may expect a number of pacing
stem revisions over decades of follow-up (see Recommen-
tions Table 1) However, later development of AV block
nnot be predicted.
.9. Single-Chamber Ventricular
acing in SND
one of the randomized trials of dual-chamber pacing vs.
ngle-chamber ventricular pacing have reported a substantial
nefit of the dual-chamber pacing mode on survival or
roke (6,8,10). Backup VVI pacing may be considered in the
tient with normal ventricular function not expected to
quire frequent pacing. Backup VVI pacing may also be
nsidered in the sedentary patient who is not likely to
quire frequent pacing, the patient with significant comor-
dities that will influence survival and other clinical out-
mes, as well as in patients in whom venous access is an
sue. Dual-chamber pacing is not beneficial, and single-
amber ventricular pacing is indicated in patients with perma-
nt AF or longstanding persistent AF if no attempt to restore
nus rhythm is planned (see Recommendations Table 1).
.10. Rate Adaptive Programming
hronotropic incompetence is common in patients with SND
d may evolve as part of the natural history of the disease,
rticularly if AV nodal drugs or other negatively chrono-
opic medications are required to manage atrial tachyarrhyth-
ias. All contemporary pacemakers have sensor systems and
e able to provide rate adaptive pacing. Rate adaptive pacing
as used predominantly, but not exclusively, in all of the
ndomized trials that included patients with SND (5–8,10).
lthough some clinical trials have reported a benefit of rate
aptive pacing on exercise tolerance over the short term, the
ng-term benefit is the subject of debate. One trial evaluated
hether dual-chamber rate adaptive pacing improved quality
life compared with dual-chamber pacing alone (12). A total
872 patients with moderate chronotropic incompetence
ere included and randomized into the two arms and fol-
wed for 1 year. Moderate chronotropic incompetence was
fined as a blunted heart rate response not exceeding 80% of
aximum predicted heart rate (220 – age) at peak exercise
ving completed at least two stages of exercise testing using
modified Bruce protocol. No difference between the two
eatment arms was observed with respect to the primary
dpoint—quality of life. Patients with rate modulation had a
gher peak exercise heart rate after 6 months, but total
ercise time was not increased with rate modulation. Fur-
ermore, more hospitalizations for heart failure were ob-
rved in the group treated with rate adaptive pacing com-
red to the group without rate adaptive pacing (7.3% vs.
5%, p 0.01). Based on these data and the concern that
ore atrial pacing may increase the risk of AF (53) rate
aptive programming is recommended only for patients with
idence of significant symptomatic chronotropic incompe-
nce and demonstrated improvement following program-
ing the rate adaptive feature. The need for rate adaptive
cing should be reassessed as part of routine follow-up since
ronotropic incompetence may evolve over time (see Rec-
mendations Table 1). di. Pacemaker Device and Mode
election for AV Block
xpert Consensus Recommendations (see Table 1 for a
mmary of consensus recommendations)
ASS I
Dual-chamber pacing is recommended in patients with AV
block (Level of Evidence: C) (22).
Single-chamber ventricular pacing is recommended as an
acceptable alternative to dual-chamber pacing in patients
with AV block who have specific clinical situations that limit
the benefits of dual-chamber pacing. These include, but are
not limited to, sedentary patients, those with significant
medical comorbidities likely to impact clinical outcomes,
and those in whom technical issues, such as vascular
access limitations, preclude or increase the risk of placing
an atrial lead (Level of Evidence: B) (22).
Dual-chamber pacing is recommended over single-chamber
ventricular pacing in adult patients with AV block who have
documented pacemaker syndrome (Level of Evidence: B)
(31–34,61).
ASS IIa
Single-lead, dual-chamber VDD pacing can be useful in patients
with normal sinus node function and AV block (e.g., the
younger patient with congenital AV block) (Level of Evidence:
C) (58,59).
VVI pacing can be useful in patients following AV junction
ablation, or in whom AV junction ablation is planned, for rate
control of AF due to the high rate of progression to permanent
AF (Level of Evidence: B) (86–89).
ASS III
Dual-chamber pacing should not be used in patients with AV
block in permanent or longstanding persistent AF in whom
efforts to restore or maintain sinus rhythm are not planned
(Level of Evidence: C) (1).
Pacemakers with ventricular pacing capabilities are indi-
ted in patients with AV conduction disturbances that
clude various degrees of intermittent or permanent AV
ock and selected patients with bifascicular block who have
cumented or presumed intermittent AV block (1). Al-
ough a patient may present with complete heart block, AV
nduction may resume and the need for pacing may be
termittent over time (49). Nevertheless, recent clinical data
ow that a number of patients with intermittent AV conduc-
on abnormalities progress to complete heart block over
nger-term follow-up (17,60). Patients with AV conduction
sease and left ventricular dysfunction and some patients
ho will be paced in the ventricle most of the time may
nefit from cardiac resynchronization therapy. As stated in
e introduction, indications for cardiac resynchronization
erapy have been published previously, and guideline up-
tes related to these indications are also in progress (1–3).
hus, specific recommendations for cardiac resynchroniza-
on therapy are not addressed in this document.
The minimum requirement for pacing in AV conduction
sease is to prevent symptoms secondary to bradycardia.
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectioneally, pacing should restore AV synchrony without ad-
rsely affecting ventricular synchrony. In patients with
rmal sinus node function, VDD pacing restores both AV
nchrony and chronotropic competence. Single-chamber
te adaptive ventricular pacing also restores chronotropic
mpetence, but not AV synchrony. AV synchrony contrib-
es significantly to cardiac output, especially at rest and
ring lower levels of exercise. It increases stroke volume by
much as 50% and may decrease left atrial pressure by up
25% (32,61). Patients with diastolic dysfunction, such as
ose with significant left ventricular hypertrophy, who de-
nd on optimized preload, likely derive the most benefit
om AV synchrony (62,63).
As discussed previously, ventricular pacing can cause
verse hemodynamic effects due to ventriculoatrial conduc-
on or atrial contraction against closed AV valves, resulting
pacemaker syndrome (30). Shortly after the introduction of
al-chamber pacemakers, several randomized controlled
ort-term studies reported that dual-chamber pacing resulted
improved symptom scores and less pacemaker syndrome
mpared with ventricular pacing (30,32,64). Based on these
udies, dual-chamber pacemakers were widely adopted in
eference to single-chamber pacemakers for the treatment of
tients with AV conduction disease.
The optimal pacing mode for patients with AV conduction
sease has been the subject of debate. Three major random-
ed clinical trials (PASE, CTOPP, and UKPACE) have
mpared dual-chamber pacing to single-chamber ventricular
cing in patients with AV block (5–7,22). These randomized
ntrolled trials included mostly elderly patients (mean age
–80 years) and many with comorbidities. PASE and
TOPP also included patients with SND, 49% and 51% had
V block as the primary indication for pacing, respectively.
nly UKPACE was limited to patients paced for AV con-
ction disease. UKPACE (22) enrolled 2,021 elderly pa-
ents (mean age 80  6 years) and randomized them to dual-
single-chamber ventricular pacing. The ventricular pacing
hort was also randomized to fixed-rate ventricular pacing or
te adaptive pacing. At entry, 20% of patients were asymptom-
ic, and 38% had intermittent AV block. For the 65% of patients
whom data were available, the percent of ventricular paced
ats was significantly lower for single-chamber vs. dual-
amber pacemakers (93% vs. 99%, p0.001). Neither CTOPP
r PASE was powered to specifically assess clinical outcomes
the subgroup of patients with an AV block indication for
cing, and neither showed a significant advantage of dual- or
ngle-chamber pacing for most outcomes measured. The effects
pacing on important clinical outcomes in patients with AV
ock as a result of these clinical trials are summarized below.
.1. AF
trial or dual-chamber pacing compared to single-chamber
ntricular pacing in the CTOPP population overall signifi-
ntly reduced the risk of AF (6,7). The incidence of AF is
wer in patients with an AV block indication for pacing
mpared to those with a SND indication for pacing (21). In
TOPP patients with an AV block indication for pacing were
ss likely to progress to permanent AF compared to those
ith a SND indication for pacing (65). In UKPACE, which included only patients with AV conduction system disease,
e annual event rates for developing AF were similar in the
al-chamber and ventricular pacing groups (2.8%/yr and
0%/yr, respectively) (Figure 2) (22).
.2. Stroke/Thromboembolism
ual-chamber pacing, compared with single-chamber ven-
icular chamber pacing, did not reduce the risk of stroke or
stemic thromboembolism in either CTOPP or UKPACE
igure 3) (6,7,22).
.3. Heart Failure
ual-chamber pacing, compared with single-chamber ven-
icular chamber pacing, did not reduce the risk of heart
ilure in either CTOPP or UKPACE (6,22).
.4. Mortality
ual-chamber pacing, compared with single-chamber ven-
icular chamber pacing, did not reduce the risk of death from
l causes or from cardiovascular causes in either CTOPP or
KPACE (Figure 1) (6,22).
.5. Exercise Capacity
hortly after the introduction of dual-chamber pacemakers,
ort-term studies reported that dual-chamber pacing resulted
improved exercise tolerance compared with fixed-rate
ntricular pacing (66). However, few studies comparing
al-chamber and rate adaptive ventricular pacing have
own similar benefit. Sulke et al. (67) performed a crossover
udy of 22 patients implanted with dual-chamber rate adap-
ve pacemakers for high-grade AV block. These authors
ported improved exercise time, functional status, and symp-
ms with DDDR compared with VVIR pacing, as well as a
rong patient preference for the DDDR pacing mode (67). In
ntrast, most crossover studies reported no significant in-
ease in exercise tolerance when dual-chamber pacing was
mpared with the VVIR pacing (68–74). In CTOPP, an
provement in exercise capacity as assessed by the distance
alked in 6 minutes was observed in a subgroup of patients
ndomized to atrial or dual-chamber pacing who had a high
gree of pacing (29).
.6. Quality of Life
mall, randomized crossover studies have reported significant
fferences in quality of life, with most individual patients
eferring dual-chamber to single-chamber pacing (Table 3)
1,67–84). These studies included patients who were capa-
e of exercising, and many had been paced in the dual-
amber mode at the time of study enrollment. Patients who
ere recruited after a period of dual-chamber pacing, or
tients who were randomized to dual-chamber pacing first,
ere more likely to request early crossover from single-
amber to dual-chamber pacing. In one study, patients
ith no reported symptoms attributed to single-chamber
ntricular pacing were revised to dual-chamber pacing at
e time of generator change. Despite their being asymptom-
ic before crossover, their symptom scores improved after
itiation of dual-chamber pacing (78).
Table 3. Comparison of Symptom Score and Patient Preference in Randomized Crossover Trials of Pacing Mode in Patients With AV Conduction Disease: Single- vs. Dual-Chamber
Pacemakers
Study n Age Pacing Indication Symptoms Patient Preference
Studies comparing physiological pacing with fixed-rate VVI pacing
Perrins 1983 (75) 13 65 (32–87) years AV block Symptoms and exercise tolerance improved with physiological
(VDD) pacing compared with VVI
More patients preferred VDD
Heldman 1990 (31) 40 Not stated Not stated Symptoms worse in VVI mode compared with dual-chamber
pacing
65% had moderate or
severe symptoms and 18%
mild symptoms in VVI
compared with DDD
Sulke 1992 (78) 16 41–84 years AV block Fewer symptoms in DDD compared with VVI 69% preferred DDD, VVI
least acceptable in 50%
Avery 1994 (69) 13 75 years AV block Fewer symptoms and increased exercise tolerance with dual-
chamber physiological pacing compared with ventricular
pacing
Physiological dual-chamber
pacing preferred
Channon 1994 (70) 16 77–88 years AV block Fewer symptoms and improved exercise ability with DDD
compared with VVI pacing
3 patients requested early
reprogramming from VVI;
11 of 16 preferred DDD
Studies comparing physiological pacing with rate adaptive VVIR pacing
Sulke 1991 (67) 22 18–81 years High-grade AV block and
chronotropic
incompetence
Perceived general well-being, exercise capacity, functional
status, and symptoms were significantly worse in the VVIR
than in dual-chamber rate responsive modes
5 in VVIR requested early
reprogramming
DDDR preferred to VVIR
Oldroyd 1991 (73) 10 23–74 years AV block No difference in symptoms and maximal exercise performance
between DDD and VVIR pacing
1 patient requested early
crossover
Lau 1994 (79) 33 66  1 years 15 AV block Fewer symptoms, better stamina, and improved quality of life
with DDDR
DDDR preferred over DDD
and VVIR
Lukl 1994 (80) 21 68  8 years 13 AV block Symptoms and quality of life improved with DDD compared
with VVIR pacing
Majority preferred DDD
Hargreaves 1995 (72) 20 80.5  1 years AV block Symptoms reduced with DDD pacing compared with VVIR or
VVI; exercise performance worse with VVI compared with DDD
or VVIR
11 preferred DDD
Deharo 1996 (71) 18 70  6.5 years AV block No significant difference in quality-of-life or cardiopulmonary
performance, but trend toward increased sense of well-being
with DDD compared with VVIR mode
3 disliked VVIR
Kamalvand 1997 (68) 48 64 years (mean) Atrial arrhythmias and
heart block
Perceived well-being better with DDDR with mode switching
compared with conventional DDDR or VVIR
DDDR preferred over VVIR
Höijer 2002 (82) 19 75.5  7.3 years 12 AV bock Quality of life was better, with less dyspnea and improved
general activity, with DDDR compared with VVIR mode
7 in VVIR requested early
crossover
11 preferred VVIR
Ouali 2010 (81) 30 76.5  4.3 years Complete Heart block Improved quality of life with DDD pacing compared with VVIR 18 preferred DDD
Pacemaker syndrome 30% VVI vs. 0% DDD, p  0.05 0 preferred VVI
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode SelectionAlthough it is clear that the majority of patients who have
ready experienced pacing, either dual-chamber or ventric-
ar, prefer dual, neither PASE (5) nor CTOPP (26) reported
gnificant differences in quality of life between single- and
al-chamber pacing in patients with AV block. A detailed
alysis of quality of life in these two randomized studies of
cing mode confirmed that pacing clearly improved quality
life over no pacing, but it did not show a difference
tween dual- and single-chamber pacing (5,26). These data
ggest that the effect of pacing mode on quality of life
pends on various factors, including the order of testing, the
tient population, and the follow-up duration. For example,
cing mode may be more important in younger, active patients
ith few comorbidities than in patients whose quality of life may
strongly influenced by comorbidities, such as the patients
rolled in the PASE study.
.7. Pacemaker Syndrome
revious studies, including a meta-analysis of patients with
ND and AV block, reported a significant reduction in
cemaker syndrome with dual-chamber pacing compared to
ngle-chamber ventricular pacing (see Recommendations
able 1 and Table 3) (33,34,67–74). However, as indicated
eviously, crossover to dual-chamber pacing is heavily
fluenced by whether this can be accomplished by repro-
amming alone in the presence of a dual-chamber pace-
aker or by a surgical intervention. For example, in PASE,
l patients received a dual-chamber pacemaker. and 26% of
tients randomized to ventricular pacing were considered to
ve pacemaker syndrome sufficiently severe to necessitate
programming the pacemaker from the VVI to DDD mode
). About half of the patients who had pacemaker syndrome
d reprogramming to the DDD mode had AV block (5).
unctional status, assessed by SF-36, improved after cross-
er in all patients (5). In contrast, in CTOPP, only 7% of
tients who were implanted with single-chamber pace-
akers and followed over 6 years underwent reoperation
r revision to a dual-chamber pacing system (7). This
parent difference in incidence may reflect variability or
e reliability of the diagnosis. It may also reflect the
eference of patients and/or physicians to consider a
cing system revision only for severe symptoms if this
quires a reoperation.
.8. Pacing Mode after AV Junction Ablation
atheter ablation of the AV node to produce complete heart
ock combined with permanent pacing is a recognized
eatment to control the heart rate and alleviate symptoms in
tients with medically refractory AF. Although this proce-
re is most often utilized in patients with persistent or
rmanent AF, AV junction ablation and pacing is also an
cepted treatment for patients with drug-refractory paroxys-
al AF (85). However, 16–35% of patients develop perma-
nt AF within the first 6 months after AV junction ablation
6–89), and this rate continues to increase during long-term
llow-up (86,88,89). The progression of AF has been attrib-
ed to the cessation of antiarrhythmic drug therapy; how-
er, even with continued antiarrhythmic drug therapy the
cidence of permanent AF is high after AV junction ablation th9,90). This high incidence of permanent AF may be due to the
favorable neurohumoral or hemodynamic consequences of
lation and/or the impact of right ventricular pacing (39).
ased on the high rate of progression to persistent or
rmanent AF following AV junction ablation, single-
amber ventricular pacing is an appropriate mode of pacing
r the majority of patients undergoing this procedure (see
ecommendations Table 1).
.9. Potential Deleterious Effects of
entricular Pacing in AV Block
ost randomized controlled trials did not report the percent
ventricular pacing in patients with AV block (5–7,22).
ecause they were not performed with pacemakers that
cluded algorithms to minimize right ventricular pacing, it is
kely that the proportion of right ventricular pacing was high.
lthough algorithms to minimize ventricular pacing are most
fective in patients with intact AV conduction (13,91,92),
ey have also been used in patients with intermittent AV
ock (49,60). One such algorithm allowed a 60% relative
duction in ventricular pacing in patients with AV block
er the short term (48). Cumulative ventricular pacing can
as low as 28% in patients with intermittent AV block (93).
owever, there is no documentation that minimizing ventric-
ar pacing is beneficial in patients with AV block. Moreover,
sufficiently large trial has evaluated the safety of such
gorithms in patients with AV block. Case reports have
dicated that the use of algorithms allowing intermittent AV
ock may have deleterious effects in some patients with AV
ock (13,55–57). Furthermore, a considerable number of
tients with intermittent AV block progress to develop
mplete heart block over longer-term follow-up (60).
.10. Single-Lead, Dual-Chamber VDD
acemakers
contrast to commonly used dual- and single-chamber
cemakers, single-lead, AV pacemakers (VDD) constitute
ss than 1% of implanted pacemakers in the United States
d 5% in Canada (94). The single ventricular lead contains
additional floating bipole for atrial sensing that permits
DD pacing. These systems can restore AV synchrony in
tients with normal sinus node function without an addi-
onal atrial lead. Thus, they may reduce procedure time and
me complications associated with dual-chamber implants.
hey are used infrequently because the atrial sensing ability
the lead has tended to degrade over time, and implanters
e concerned about the potential need for atrial pacing if
ND develops (95–96). However, a VDD pacing system can
ve a potential role in the management of the younger
tient, such as the patient with congenital heart block who
ight expect multiple system revisions over decades of
llow-up (see Recommendations Table 1).
.11. Factors Influencing Choice
f DDD over VVI
everal factors may influence the choice of dual-chamber vs.
ngle-chamber ventricular pacing. It should first be noted
at patients might present with evidence for both SND and
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curring in about 30% (8,10). All of the randomized clinical
ials compared outcomes in AV block in an elderly popula-
on (Table 2). Data on younger patients are limited. Among
e consensus panel, dual-chamber pacing is preferred for the
unger or more physically active patient in whom there is a
rong desire to preserve AV synchrony and chronotropic
sponse driven by the sinus node rather than by an imperfect
tivity sensor (see Recommendations Table 1) (30,61,97).
here is also a preference for dual-chamber pacing in patients
ith any degree of systolic dysfunction and/or diastolic
sfunction in whom the maintenance of AV synchrony is
ore important for preserving optimal hemodynamics than
art rate alone (98–101). The atrial arrhythmia detection
atures in dual-chamber pacemakers also permit detection of
rial tachyarrhythmias that may result in therapeutic inter-
ntions, including therapy for stroke prevention (23–24).
ual-chamber pacing is not beneficial, and single-chamber
ntricular pacing is indicated in patients with permanent AF
longstanding persistent AF if no attempt to restore sinus
ythm is planned (see Recommendations Table 1).
. Other Indications
he writing committee did not address pacing mode for every
dication identified in the current Device-Based Therapy of
ardiac Rhythm Abnormalities (1) as there are limited to no
ta on pacing mode for some less frequent indications (e.g.,
llowing cardiac transplantation, sarcoidosis, and muscular
strophy). Consensus recommendations on pacemaker de-
ce and mode selection are provided for the following
nditions where a clinical decision for pacing has already
een made: hypersensitive carotid sinus syndrome, neuro-
rdiogenic syncope, long QT syndrome, and hypertrophic
rdiomyopathy.
.1. Pacemaker Device and Mode Selection
r Hypersensitive Carotid Sinus Syndrome
xpert Consensus Recommendations (see Table 1)
ASS IIa
Dual-chamber or single-chamber ventricular pacing can be
useful for patients with hypersensitive carotid sinus syndrome
(Level of Evidence: B) (102–106).
ASS III
Single-chamber AAI pacing is not recommended for patients
with hypersensitive carotid sinus syndrome (Level of Evidence: C)
(102).
Hypersensitive carotid sinus syndrome is defined as syn-
pe or presyncope resulting from an exaggerated reflex in
sponse to carotid sinus stimulation. There are two compo-
nts of the reflex: the cardioinhibitory component, which is
kely due to excess parasympathetic tone, causing slowing of
e sinus rate with prolongation of the PR interval or even
mplete or high-grade AV block, and the vasodepressor
mponent, which is due to inhibition of sympathetic dis-
arge leading to vasodilatation and hypotension, indepen-
nt of heart rate changes. The response to carotid massage vaay not necessarily reproduce the clinical events that may
cur in a variety of positions and under a variety of
nditions. Moreover, even in a single individual, there is no
ason to suspect that hypersensitive carotid response is a
producible phenomenon.
No large randomized clinical trials of pacing mode have
en conducted in this syndrome. Nevertheless, the impact of
cing mode in patients with syncope and hypersensitive
rotid sinus syndrome has been evaluated in a few studies.
AI pacing alone has been shown to be ineffective in this
ndrome (102), presumably due to concomitant AV block
ring carotid sinus activation. In a 17-year prospective study
89 patients with hypersensitive carotid sinus syndrome, in
hich males outnumbered females 4.5:1 (age range at symp-
m onset 37–88 years, average 63 years), not one case of
current syncope occurred after single-chamber VVI pace-
aker implantation (103). In a prospective randomized study
pacing vs. no pacing therapy performed in 60 patients with
rotid sinus syndrome, syncope recurred in 16 (57%) of the
-pacing group and in only 3 (9%) of the pacing group (p 
0002), while 18 of 32 (56%) of the paced group received
VI devices and the remainder received DDD devices (104).
ata from two studies of patients with hypersensitive carotid
nus syndrome reported that VVI pacing in this age group
s been associated with a high (30–50%) incidence of
tolerance, driven primarily by pacemaker syndrome
05,106). As indicated previously, preimplantation testing to
edict pacemaker syndrome and intolerance to VVI pacing
aid in mode selection is imperfect (33).
A recent prospectively designed, double-blind study has
en conducted to assess pacing mode on clinical outcomes
patients with carotid sinus syndrome (107). In this small
ossover study, comparisons were made between VVI vs.
DDR vs. DDDR with rate drop response in patients with
rotid sinus syndrome without evidence of concomitant
ND or AV block. The primary endpoints of syncope or
esyncope were significantly reduced after pacemaker im-
antation in all three groups, and no significant differences in
e primary outcomes were demonstrated among the three
cing modalities. SF-36 scores revealed some minor benefits
DDDR pacing vs. baseline in the categories, but no pacing
ode was found to be superior. The development of pace-
aker syndrome was not seen in any group. Despite the
ysiological hemodynamic advantage of AV synchrony, the
periority of DDD pacing was not observed in this study.
udden bradycardia response algorithms are designed to
entify preemptively the onset of a reflex-mediated cardioin-
bitory event and initiate a high-rate pacing intervention that
tatively intercedes and aborts the episode. The results from
is small randomized study suggest no clear advantage to
is manner of pacing. Patients with pure vasodepressor
ncope related to carotid sinus hypersensitivity were not
rolled in this study. It remains unclear whether this group
rives benefit from the sudden bradycardia/rate-drop re-
onse algorithms.
Based on our knowledge of the pathophysiology of hyper-
nsitive carotid sinus syndrome, there is a potential benefit
dual-chamber pacing to minimize the impact of the
sodepressor response and prevent pacemaker syndrome.
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August 14, 2012:682–703 HRS/ACCF Pacemaker Mode Selectionowever, ventricular pacing seems to be effective in prevent-
g syncope (see Recommendations Table 1).
.2. Neurocardiogenic Syncope
xpert Consensus Recommendations (Table 1)
ASS IIa
Dual-chamber pacing can be useful for neurocardiogenic syn-
cope (Level of Evidence: C) (109–114).
ASS III
Single-chamber AAI pacing is not recommended for neurocar-
diogenic syncope (Level of Evidence: C).
Similar to hypersensitive carotid sinus syndrome, patients
ith neurocardiogenic syncope may experience a cardioin-
bitory response, a vasodepressor response, or both. Brady-
rdia usually accompanies neurocardiogenic syncope during
lt table testing and may be more often recorded during
inical episodes. Data supporting the use of pacemakers for
urocardiogenic syncope are scant (108), and there is a large
acebo effect associated with pacing (109–112). Early stud-
s published between 1980 and 1994 suggested that pacing is
eful in patients with predominantly cardioinhibitory va-
vagal responses and that pacing eliminated symptoms in
% of these patients and prevented abrupt cardiovascular
llapses (113). However, recent randomized trials have
iled to confirm a substantial impact of pacing for prevention
syncope in neurocardiogenic syncope (109,114). The VPS
trial showed a trend in the direction of a benefit from pacing
10). This study may have been underpowered to detect a
ysiological response to pacing, as the design did not
nsider the strength of a placebo effect as a component of
cemaker benefit. Other studies evaluating the role of pacing
the treatment of this condition are ongoing (115).
In the clinical context, patients with neurocardiogenic
ncope, particularly those with profound episodes of asys-
le (e.g., pauses 10 seconds), may benefit from cardiac
cing. Some patients with neurocardiogenic syncope have
derlying sinus bradycardia and associated high vagal tone.
urthermore, the premonitory rate drop prior to syncope can
rather prolonged, with a total duration of the cardioinhib-
ory reflex lasting 85 seconds (range 47–116 seconds) (116).
n atrial (AAI) pacemaker should not be used in an individ-
l who may have episodic transient AV block due to
gmented parasympathetic activation. If the clinical decision
s been made to implant a pacemaker, a dual-chamber
cemaker should be selected to preserve AV synchrony,
inimize ventricular pacing, and provide rate modulation in
sponse to a sudden drop in heart rate (see Recommenda-
ons Table 1). VVI pacing has not been tested in this context.
.3. Long QT Syndrome
xpert Consensus Recommendations (Table 1)
ASS I
Dual-chamber or atrial pacing compared to ventricular pacing is
recommended for symptomatic or high-risk patients with con-
genital long QT syndrome (Level of Evidence: C) (117–119). paThe long QT interval syndrome can lead to episodic
adycardia-dependent torsades de pointes ventricular tachycar-
a (VT) causing presyncope, syncope, or cardiac arrest. While
pacemaker will not treat ventricular fibrillation that might
velop in patients with long QT syndrome, it may be
neficial in patients who have recurrent episodic torsades de
intes due to bradycardia. Indeed, no studies have compared
cing therapy to ICD therapy for prevention of syncope or
dden cardiac arrest in the setting of long QT syndrome. It
recognized that ICD therapy might be recommended in
mptomatic or high-risk long QT syndrome patients, and the
ove recommendations that apply specifically to pacemaker
ode selection may not be applicable to all patients receiving
Ds. For instance, a single-chamber ICD may be preferred
some situations, especially in children and adolescents, to
inimize lead complications and maximize device longevity.
Unfortunately, the literature regarding the benefits of
cing and selection of pacing mode in this syndrome is very
mited. In one study of eight patients, pacing was instituted
three who were unsuccessfully treated with both beta-
ockers and left cardiothoracic sympathectomy, and in two
ho proved refractory or intolerant to beta-blockers. After
cing using DDD, AAI, or VVI devices (70–85 bpm), there
as no change in the corrected QT interval, but the measured
T interval decreased significantly. In long-term follow-up,
l patients were alive and syncope-free. One patient with an
AI pacemaker developed dizziness due to AV block but
mained asymptomatic after DDDR pacing (117).
From an international prospective study of long QT syn-
ome patients, 30 patients were identified who had under-
ne permanent pacemaker implantation (AAI, VVI, or
DD) for the management of recurrent syncope (118). Pacing
duced the rate of recurrent syncopal events in high-risk long
T syndrome patients, but pacing did not provide complete
otection with recurrent syncope or ventricular arrhythmias
curring in 9 patients. The effect of pacing on repolarization
as evaluated in 10 patients in whom the demand atrial
cing rate was faster than the intrinsic rate, and a significant
duction in QT interval with a nonsignificant reduction in
rrected QT interval was noted. Another study suggested
at combined beta-blocker therapy and pacing (DDD, AAI,
VVI) at a rate designed to normalize the QT interval
peared effective for symptomatic patients with long QT
ndrome, although one sudden death occurred in a patient
ho had discontinued beta-blocker therapy (119).
Atrial pacing alone may be effective as it prevents brady-
rdia that causes torsades de pointes VT, and since most of
ese individuals have normal AV conduction, they do not
quire ventricular pacing. No randomized studies have
mpared the efficacy of a specific pacing mode for long QT
ndrome. A dual-chamber pacemaker in this population may
lp detect episodes of VT with device monitoring that might
pact patient management. It is possible that ventricular
cing in this population may lead to an increased risk of
normal ventricular repolarization that could increase the
sk for torsades de pointes VT (120). Based on these
nsiderations, dual-chamber pacing might be preferred for
tients with long QT syndrome and syncope secondary to
use-dependent VT (see Recommendations Table 1).
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xpert Consensus Recommendations (Table 1)
ASS IIA
Dual-chamber pacing can be useful for patients with medically
refractory, symptomatic hypertrophic cardiomyopathy with sig-
nificant resting or provoked left ventricular outflow obstruction
(Level of Evidence: C) (121–124).
ASS III
Single-chamber (VVI or AAI) pacing is not recommended for
patients with medically refractory, symptomatic hypertro-
phic cardiomyopathy (Level of Evidence: C) (124).
Hypertrophic obstructive cardiomyopathy is associated
ith diastolic dysfunction and obstruction to aortic outflow.
ata are limited, and there is considerable controversy
garding the potential benefit of pacing in this setting. The
ncept that dual-chamber pacing may improve symptoms,
duce the left ventricular outflow tract gradient, and poten-
ally reduce the risk of episodic AF is not supported by
rong clinical evidence, although initial trials suggested
nefit (121–123).
The M-PATHY Trial was a prospective, multicenter trial
sessing pacing in 48 patients with symptomatic drug-
fractory hypertrophic obstructive cardiomyopathy who
ere randomized to DDD pacing or pacing backup (AAI-30)
a double-blind, crossover study design followed by an
controlled and unblinded 6-month pacing trial (124). No
nefit of pacing was seen for subjective or objective mea-
res of symptoms or exercise capacity. After unblinded
cing, functional class and quality-of-life score were im-
oved compared with baseline, but peak oxygen consump-
on was unchanged. Outflow gradient decreased in 57% of
tients but showed no change or was increased in 43%.
hese data indicated that pacing is not a primary treatment for
structive hypertrophic cardiomyopathy, and there was a
bstantial placebo effect from pacing (124). A placebo effect
as also suggested in another small double-blind trial that
ndomized DDD pacing to backup AAI pacing for 3 months,
subjective symptomatic improvement occurred with im-
antation of a pacemaker even without any hemodynamic
nefit (125).
In the absence of symptomatic AV block or SND in
ble 4. Perioperative Complications for DDD and VVI Pacing Sy
pe of Complication
CTOPP
Dual
(n  1,084)
Ventricular
(n  1,474) p Value (n
y 9.0% 3.8%
eumothorax 1.8% 1.4% 0.001
morrhage 0.2% 0.4% 0.42
adequate pacing 1.3% 0.3% 0.32
adequate sensing 2.2% 0.5% 0.002
vice malfunctioning 0.2% 0.1% 0.001
ad dislodgement 4.2% 1.4% 0.4tients with hypertrophic cardiomyopathy, ventricular pac- dug offers no benefit and could be detrimental. AAI pacing is
t useful as the goal of pacing therapy is to maintain AV
nchrony and create ventricular preexcitation. Thus, for the
edically refractory patient in whom the clinical decision has
en made to implant a pacemaker, dual-chamber pacing is
commended (see Recommendations Table 1).
. Complications Related to Pacing
.1. Implant Complications
able 4 summarizes implant-related complications for dual-
amber and ventricular pacing. The overall complication
te was higher for dual-chamber pacing systems, compared
single-chamber ventricular pacing systems, as reported by
e CTOPP and UKPACE Investigators (6,22). About half
these complications were atrial lead dislodgements that
quired surgical correction, and half were atrial sensing or
cing problems that did not require reoperation. In
KPACE, patients in the dual-chamber group were more
kely to need a therapeutic intervention (8.8% vs. 5.6%,
0.001) and to undergo a repeat procedure prior to
spital discharge (4.2% vs. 2.5%, p  0.04) than those in
e single-chamber group.
.2. Complications Secondary to
acing System Modifications
lthough clinicians may favor starting with a single-chamber
vice in most patients with the intent to upgrade the device
a dual-chamber device if a patient develops AV block (with
AI pacemakers) or pacemaker syndrome (with VVI pace-
akers), upgrading a device can be technically challenging
d is associated with an increased risk of complications. The
gher rate of initial implant complications for dual-chamber
cemakers is offset by the subsequent need to insert an atrial
ad in some patients with single-chamber pacemakers during
llow-up. In CTOPP, this upgrade rate was 4.3% in the first
years, and during long-term follow-up the rate of upgrade to
dual-chamber pacing system remained 1%/year (6,7). In
e retrospective study of 44 patients who underwent up-
ade from a single-chamber to a dual-chamber device, 20
tients (45%) experienced one or more complications. This
d the authors to conclude that, compared with single- or
UKPACE MOST PACE
)
Ventricular
(n  1,009) p Value Dual Dual
3.5% 0.001 4.8% 6.1%
— — 1.5% 2%
— — — —
— — — —
— — — —
— — — —
2.5% 0.04 Atrial 1.9%,
ventricular 1.1%
Atrial 0.5%,
ventricular 1.7%stems
Dual
 1,012
7.8%
—
—
—
—
—
4.2%al-chamber implantation, pacemaker upgrades take longer
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egistry prospectively assessed procedure-related complica-
ons associated with pacemaker or ICD generator replace-
ents over 6 months of follow-up. In the group of patients
ho also underwent a planned transvenous lead addition, the
te of major complications was 15.3% (95% CI 12.7–18.1).
he authors concluded that pacemaker generator replace-
ents with addition of a transvenous lead are associated with
appreciable complication risk (127).
. Cost and Cost-Effectiveness of
ual- Versus Single-Chamber Pacemakers
itial hospitalization costs are higher for dual- vs. single-
amber pacemakers, primarily because of the more expen-
ve pulse generator and additional lead and the potential for
gher rates of complications associated with dual-chamber
cemakers that are largely driven by atrial lead dislodge-
ent. The reported differential initial cost between the two
stems is in the range of $2,200–$2,600 (128,129). Indeed,
veral studies have assessed the economic implications of
planting a ventricular or dual-chamber pacemaker in patients
ith SND and AV block. Instead of just examining the absolute
fference in cost between the two systems, these studies present
st-effectiveness analyses that also take into account differences
effectiveness between the two systems and, in some cases,
just the results for quality of life. Indeed, such analyses are
fected by many factors, including whether all important and
levant costs and effects are included, the perspective from
hich the costs and benefits are to be considered, whether direct
d indirect costs are accounted for, the length of follow-up, and
e method used to adjust the results for time. Differences in any
these factors may lead to different results.
In one analysis conducted by the Italian government, the
cremental cost-effectiveness ratio of implanting a dual vs. a
ntricular device was 260 Euros/quality-adjusted life year
ALY) (approximately US $330/QALY). Importantly, de-
ce replacement rates due to pacemaker syndrome had the
ggest impact on the final results. Thus, the higher initial
sts of the dual-chamber device implants appeared to be
fset by a reduction in costs associated with repeat proce-
res and treatment of AF (130). Another study conducted in
e United Kingdom examined the health and economic conse-
ences of implanting a dual-chamber vs. a ventricular pace-
aker for SND or AV block. That study demonstrated that the
ditional health benefits from dual-chamber pacing are
hieved at a mean net cost of £43 per patient, resulting in a
st-effectiveness ratio of £477/QALY (approximately US $739/
ALY). Therefore, although implanting a dual-chamber device
creases the cost of the initial procedure, this is expected to be
unterbalanced by a reduction in costs associated with repeat
ocedures and the management of AF (131).
In CTOPP, the incremental cost-effectiveness of physiological
cing was estimated from the viewpoint of a provincial gov-
nment health care payer. The incremental cost-effectiveness of
al-chamber pacemakers was CAN $297,600 per life year
ined (approximately US $290,482) and CAN $74,000 per AF
ent avoided (approximately US $72,230) (129). Based on
ly mortality and prevention of AF (and not considering ofcemaker syndrome and quality of life), physiological pacing
d not appear to be economically attractive in the short term;
wever, long-term studies incorporating all nonfatal cardiac
ents, pacemaker syndrome, and quality of life may provide a
ore accurate assessment of the cost-effectiveness of physiolog-
al pacing (129).
Using a Markov model, a cost-effectiveness analysis of
OST showed that during the first 4 years, dual-chamber
cemakers increased quality-adjusted life expectancy by
013 year per subject with an incremental cost-effectiveness
tio of $53,000/QALY gained. Over a lifetime, dual-
amber pacing was projected to increase quality-adjusted
fe expectancy by 0.14 year with an incremental cost-
fectiveness ratio of about $6,800/QALY gained. Thus, this
alysis demonstrated that for patients with SND, dual-
amber pacing increases quality-adjusted life expectancy at
cost that is generally considered acceptable (128).
Although not specifically examined in these cost–benefit
alyses, it is anticipated that battery technology as well as
vice programming will also impact on cost-effectiveness.
egardless of whether single- or dual-chamber devices are
lected, programming should be optimized to enhance bat-
ry longevity and reduce cost.
. Values and Preferences
imilar to guideline documents, this consensus document
es a grading system that separates the quality of evi-
nce from the strength of recommendations. In this
cument, we have already considered factors that impact
the quality of life and functional status, such as
cemaker syndrome, right ventricular pacing, and AF
hile noting how these factors may influence mode selec-
on. We recognize that in addition to the quality of the
idence, several other factors might affect the class of
commendations. These factors are not represented in our
ficial recommendations as the current class of recom-
endations focuses largely on scientific evidence. Alter-
te grading systems may consider the balance between
sirable and undesirable effects of a therapy, patient and
ysician values, and preferences in the provision of
inical care, as well as cost of therapy for determining the
rength of recommendations (132,133).
In arriving at our recommendations, we considered
ctors such as the desirable effect of AV sequential pacing
prevent AF and the undesirable effects of ventricular
cing to cause pacemaker syndrome or promote AF. We
nsidered the values and preferences of patients to avoid
F or pacemaker syndrome. We also present examples
here patient conditions influence decision of pacing
ode. For instance, a young active patient who has SND
d normal AV and ventricular conduction may elect an
AI pacemaker to minimize hardware and reduce the risk
complications. Or a sedentary patient with prostate
rcinoma and SND who has syncope with prolonged
uses and subclavian venous stenosis with limited venous
cess may accept single-chamber backup pacing rather
an undergo a more complex procedure to allow insertion
a second lead.
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HRS/ACCF Pacemaker Mode Selection August 14, 2012:682–703In summary, guideline documents and consensus state-
ents should be used to assist health care providers in
inical decision-making by describing generally accepted
proaches for patient management based on review of the
terature and a consensus from experts. However, as in all
ch documents, “the ultimate judgment regarding care of
particular patient must be made by the health care
ovider and the patient in light of all of the circumstances
esented by that patient” (1). It is acknowledged that there
ill be circumstances in which deviations from guidelines
consensus recommendations are appropriate.
. Conclusions
atients with SND may derive benefit from atrial or
al-chamber pacing compared with ventricular pacing
ith regard to the risks of AF, stroke, pacemaker syn-
ome, and improved quality of life. Over the long term,
al-chamber pacing may be cost-effective. In patients
ith AV block, although dual-chamber pacing compared
ventricular pacing has equivalent effects on major
rdiovascular outcomes including mortality, stroke, heart
ilure, and AF, it can reduce the incidence of pacemaker
ndrome and improve some indexes of quality of life. For
ss common indications for pacing, the recommendations to
nsider dual-chamber pacing are based on small clinical Vudies. It is unlikely that large randomized trials will ever
conducted in these unique clinical subgroups. While
plant complications are more frequent for dual-chamber
an single-chamber pacemakers, the higher risk of com-
ications for dual-chamber pacemakers is offset over time
the need to reoperate on a number of patients with
ngle-chamber pacemakers for AV block or pacemaker
ndrome. Estimates of the cost-effectiveness of dual-
amber pacemakers vary widely and should not be the
minant factor determining pacing device and mode
lection.
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